Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | Director | June 20, 2018 | June 22, 2018 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| MyoKardia, Inc.MYOK · Entity 145206 | Director | November 29, 2016 | December 01, 2016 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 29, 2021 | July 01, 2021 |
| Population Health Investment Co., Inc.PHIC · Entity 136038 | Director | January 26, 2021 | January 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 919,876 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 919,876 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Global Blood Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 · Expires 2028-06-19 | Direct | 15,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
MyoKardia, Inc.
Report date November 29, 2016 · Filed December 01, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2016-11-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-11-29 · Other · Disposed 0 · Balance 0 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 6,496 |
Reported balance
Holding disclosure · report date 2016-11-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,496 F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above.
PLIANT THERAPEUTICS, INC.
Report date June 29, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.20 · Expires 2031-06-28 | Direct | 13,286 |
Reported balance
After 2021-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-29 · Grant · Acquired 13,286 · Balance 13,286 F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.
Population Health Investment Co., Inc.
Report date January 26, 2021 · Filed January 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 43,125 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Other · Acquired 43,125 · Balance 43,125 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date March 28, 2019 · Filed April 01, 2019
Section 16 reporting ended · disclosed 2019-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.59 · Expires 2029-03-27 | Direct | 10,000 |
Reported balance
After 2019-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-28 · Grant · Acquired 10,000 · Balance 10,000 F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2016 Filed Nov 16, 2016 21:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-033677 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of Third Rock Ventures III, L.P. ("TRV III"). The reporting person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 21:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-033677 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of Third Rock Ventures II, L.P. ("TRV II"). The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document |
| November 14, 2016 Filed Feb 15, 2018 02:57 UTC Amendment | Global Blood Therapeutics, Inc. GBT · Entity 123220 | OtherCOMMON STOCK | 14,611 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004081 · doc5a.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Charles Homcy Revocable Trust Disclosed balance after: 14,611 F1 · kind: This transaction was omitted from the Reporting Person's original Form 5, and the shares were not deducted from the Reporting Person's holdings in all Forms 4 filed by the Reporting Person after his original Form 5 was filed. Read SEC document |
| November 14, 2016 Filed Feb 15, 2018 02:57 UTC Amendment | Global Blood Therapeutics, Inc. GBT · Entity 123220 | OtherCOMMON STOCK | 14,611 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004081 · doc5a.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,117 F1 · kind: This transaction was omitted from the Reporting Person's original Form 5, and the shares were not deducted from the Reporting Person's holdings in all Forms 4 filed by the Reporting Person after his original Form 5 was filed. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 22:56 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | OtherCommon Stock | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032855 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On November 3, 2016, Third Rock Ventures II, L.P. ("TRV II") distributed, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On November 3, 2016, Third Rock Ventures II, L.P. ("TRV II") distributed, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document |
| November 03, 2016 Filed Feb 15, 2017 00:08 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | OtherCommon Stock | 14,611 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004068 · doc5.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,296 F1 · kind: Includes 14,611 shares received by the Reporting Person in a distribution-in-kind by Third Rock Ventures II, L.P. ("TRV II") on November 3, 2016, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended, as reported on Form 4s filed by the Reporting Person on November 7, 2016 and November 16, 2016. This report is being filed with respect to this transaction solely to correct the total number of shares held by the Reporting Person immediately following the transaction. F1 · balance_after: Includes 14,611 shares received by the Reporting Person in a distribution-in-kind by Third Rock Ventures II, L.P. ("TRV II") on November 3, 2016, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended, as reported on Form 4s filed by the Reporting Person on November 7, 2016 and November 16, 2016. This report is being filed with respect to this transaction solely to correct the total number of shares held by the Reporting Person immediately following the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.